When standard-dose treatment for allergic rhinitis isn't enough, patients face a simple question: double the dose, or add a second drug?
A new systematic review with dose-response network meta-analysis, including 262 studies, was designed to answer that question for the ARIA-EAACI 2024-2025 guidelines. There were almost no trials directly comparing the two strategies, so the authors used dose-response modelling to compare double-dose monotherapy with standard-dose co-medication.
The most useful finding is that the best next step depends on where you start.
If you start intranasal, double the intranasal drug
Doubling intranasal medication beat adding an oral antihistamine (OAH) to intranasal medication. Doubling an intranasal corticosteroid (INCS) beat adding an intranasal antihistamine (INAH).
Specifically:
Doubling an intranasal antihistamine, particularly azelastine, beat adding an OAH such as fexofenadine or loratadine for nasal symptoms, with a small but meaningful difference.
Doubling INCS versus adding OAH showed trivial differences for nasal symptoms in the main analysis, but doubling INCS gave better quality-of-life scores on the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ).
Doubling INCS beat INCS + INAH for both nasal symptoms and quality of life.
That matters because reaching for an oral pill when a nasal spray feels insufficient is a common habit. Allergic rhinitis is primarily a nasal mucosal disease, and local treatment acts where inflammation is. An oral antihistamine blocks only histamine systemically and does little for congestion, often the most bothersome symptom.
If you start oral, add an intranasal steroid
The direction flips here:
OAH + INCS beat doubling OAH for nasal symptoms and quality of life. The benefit was moderate for levocetirizine + ciclesonide versus double-dose levocetirizine, and small but meaningful for loratadine + fluticasone propionate versus double-dose loratadine.
So the emerging rule is simple:
Starting intranasal? Consider doubling the intranasal drug before adding an oral pill.
Starting oral? Consider adding an INCS rather than doubling the oral pill.
Safety
No relevant safety differences emerged. For adverse events, 203 studies and 84,838 participants were included; for withdrawal due to adverse events, 183 studies and 87,148 participants. In nearly all comparisons, differences between doubling dose and co-medication were trivial.
That does not mean double dosing is risk-free for everyone. Local effects such as nasal irritation or epistaxis still need monitoring, and escalation should stay within the approved dose for that product and patient.
What this does not mean
This is not a recommendation to double every spray. Most included studies had high or unclear risk of bias, many estimates were indirect, and some classes were represented by a single drug in certain analyses. The authors also stress that cost, availability, taste, onset of action, corticosteroid concerns, and patient preference matter alongside efficacy and safety.
It also does not erase the value of INCS + INAH fixed combinations as a starting or combination option. The question here is narrower: when escalating from INCS monotherapy, doubling INCS looked better than adding INAH in this network.
Bottom line
Doubling intranasal therapy beat adding an oral antihistamine, and doubling INCS beat adding an intranasal antihistamine, for nasal symptoms and quality of life. Safety differences were not clinically relevant. It is the best available synthesis for a question with no direct trials, and a strong reason to run those trials next.
References
Sousa-Pinto B, et al. Treatment Dose Increase Versus Co-Medication in Allergic Rhinitis: Systematic Review With Dose-Response Network Meta-Analysis. Allergy. pp. 3797-3812. 262 studies included; 256 in meta-analyses. Dose-response network meta-analysis comparing double-dose monotherapy versus standard-dose co-medication for TNSS, TOSS, RQLQ, adverse events, and withdrawal due to adverse events. Informs ARIA-EAACI 2024-2025 guidelines.
Sousa-Pinto B, et al. Protocol for systematic review comparing dose increase versus co-medication in allergic rhinitis. PROSPERO CRD420251113186, as cited in the review methods.
Bousquet J, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines and EAACI 2024-2025 guideline process, as referenced by Sousa-Pinto et al.